Quick Answer
Serina Therapeutics, Inc. reported Research And Development Expense of $13.16 million for the year ending 2025.
- Serina Therapeutics, Inc. showed an increase of +75.9% in Research And Development Expense from 2024 to 2025.
- This data is from Serina Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $1.59 million | Q2 2018: $1.38 million | Q3 2018: $1.33 million | Q1 2019: $1.34 million | Q2 2019: $1.65 million | Q3 2019: $1.45 million | Q1 2020: $1.22 million | Q2 2020: $935.0 thousand | Q3 2020: $653.0 thousand | Q1 2021: $324.0 thousand | Q2 2021: $481.0 thousand | Q3 2021: $275.0 thousand | Q1 2022: $396.0 thousand | Q2 2022: $259.0 thousand | Q3 2022: $162.0 thousand | Q1 2023: $399.0 thousand | Q2 2023: $479.0 thousand | Q3 2023: $603.0 thousand | Q1 2024: $1.11 million | Q2 2024: $1.59 million | Q3 2024: $2.42 million | Q1 2025: $2.95 million | Q2 2025: $3.15 million | Q3 2025: $3.65 million.
- Over the full 9 years of available data (2017 to 2025), Serina Therapeutics, Inc.'s Research And Development Expense has grown by 127.4%.
- Historical annual values: Fiscal year 2025: $13.16 million | Fiscal year 2024: $7.48 million | Fiscal year 2023: $2.39 million | Fiscal year 2022: $1.03 million | Fiscal year 2021: $1.46 million | Fiscal year 2020: $3.71 million | Fiscal year 2019: $5.90 million | Fiscal year 2018: $5.83 million | Fiscal year 2017: $5.78 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: